Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 7, 2015, Pages 1197-1204

  Kanogawa, Naoya ^a   Ogasawara, Sadahisa ^a   Chiba, Tetsuhiro ^a   Saito, Tomoko ^a   Motoyama, Tenyu ^a   Suzuki, Eiichiro ^a   Ooka, Yoshihiko ^a   Tawada, Akinobu ^a   Kanda, Tatsuo ^a   Mikami, Shigeru ^b   Azemoto, Ryosaku ^c   Kaiho, Takashi ^c   Shinozaki, Masami ^d   Ohtsuka, Masayuki ^a   Miyazaki, Masaru ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kikkoman General Hospital   (Japan)

^c KIMITSU CHUO HOSPITAL   (Japan)

^d Numazu City Hospital   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Milan criteria; Sustained virologic response

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; INTERFERON;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; TIME TO BEYOND THE MILAN CRITERIA; VIROLOGY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SURVIVAL RATE;

EID: 84931066233     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12925     Document Type: Article

References (43)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010; 127: 2893-2917.
2. Shiratori Y, Shiina S, Imamura M etal. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22: 1027-1033.
3. Kiyosawa K, Umemura T, Ichijo T etal. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-S26.
4. Kumada T, Nakano S, Takeda I etal. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92.
5. Shimada M, Takenaka K, Gion T etal. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111: 720-726.
6. Nagasue N, Uchida M, Makino Y etal. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology 1993; 105: 488-494.
7. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann. Surg. 1999; 229: 216-222.
8. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann. Surg. 2003; 238: 703-710.
9. Shiina S, Tateishi R, Arano T etal. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am. J. Gastroenterol. 2012; 107: 569-577.
10. Kudo M. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008; 75 (Suppl. 1): 30-41.
11. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J. Viral Hepat. 2010; 17: 287-292.
12. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2010; 32: 851-858.
13. Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int. J. Cancer 2009; 124: 2982-2988.
14. Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS ONE 2013; 8: e61361.
15. Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J. Surg. Oncol. 2013; 11: 240.
16. Kudo M, Sakaguchi Y, Chung H etal. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007; 72 (Suppl. 1): 132-138.
17. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol. Res. 2010; 40: 8-13.
18. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 2009; 50: 1142-1154.
19. Lee MH, Yang HI, Lu SN etal. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 2010; 28: 4587-4593.
20. Mazzaferro V, Romito R, Schiavo M etal. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
21. Hagihara H, Nouso K, Kobayashi Y etal. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int. J. Clin. Oncol. 2011; 16: 210-220.
22. Tanimoto Y, Tashiro H, Aikata H etal. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann. Surg. Oncol. 2012; 19: 418-425.
23. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
24. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
25. Kudo M, Izumi N, Kokudo N etal. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 2011; 29: 339-364.
26. Omata M, Lesmana LA, Tateishi R etal. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 2010; 4: 439-474.
27. Shiratori Y, Kato N, Yokosuka O etal. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997; 113: 558-566.
28. Martinot-Peignoux M, Boyer N etal. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 1998; 29: 214-223.
29. Lee SS, Heathcote EJ, Reddy KR etal. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J. Hepatol. 2002; 37: 500-506.
30. Shiratori Y, Shiina S, Teratani T etal. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 2003; 138: 299-306.
31. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J. Gastroenterol. Hepatol. 2005; 20: 1553-1559.
32. Jeong SC, Aikata H, Katamura Y etal. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J. Gastroenterol. 2007; 13: 5343-5350.
33. Suou T, Mitsuda A, Koda M etal. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol. Res. 2001; 20: 301-311.
34. Ikeda K, Arase Y, Saitoh S etal. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232.
35. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 71-75.
36. Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010; 376: 1441-1442.
37. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 2013; 13: 535-542.
38. Akamatsu M, Yoshida H, Shiina S etal. Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2004; 16: 459-466.
39. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
40. Manns M, Marcellin P, Poordad F etal. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426.
41. Sulkowski MS, Gardiner DF, Rodriguez-Torres M etal. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 2014; 370: 211-221.
42. Feld JJ, Kowdley KV, Coakley E etal. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N. Engl. J. Med. 2014; 370: 1594-1603.
43. Kowdley KV, Gordon SC, Reddy KR etal. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 2014; 370: 1879-1888.